Achaogen, Inc. (NASDAQ:AKAO) – Investment analysts at SunTrust Banks issued their Q3 2018 earnings per share estimates for Achaogen in a research note issued to investors on Thursday. SunTrust Banks analyst E. Nash anticipates that the biopharmaceutical company will earn ($0.77) per share for the quarter.
A number of other equities analysts have also recently weighed in on AKAO. Stifel Nicolaus decreased their price objective on shares of Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, November 9th. Mizuho reissued a “buy” rating and issued a $28.00 price objective on shares of Achaogen in a research report on Thursday, September 28th. BidaskClub cut shares of Achaogen from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Achaogen in a research report on Thursday, November 9th. Finally, Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating and set a $27.00 price objective for the company in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $25.78.
ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2017/11/14/achaogen-inc-akao-expected-to-earn-q3-2018-earnings-of-0-77-per-share.html.
Achaogen (NASDAQ:AKAO) traded down $0.28 during trading hours on Monday, reaching $13.01. 545,500 shares of the company’s stock were exchanged, compared to its average volume of 859,064. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.99 and a quick ratio of 6.99. Achaogen has a one year low of $4.67 and a one year high of $27.79.
Achaogen (NASDAQ:AKAO) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The company had revenue of $0.58 million during the quarter, compared to analyst estimates of $2.09 million. During the same quarter in the prior year, the company posted ($0.41) earnings per share. The firm’s revenue for the quarter was down 96.4% on a year-over-year basis.
In other news, COO Blake Wise sold 3,576 shares of the stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total transaction of $57,180.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.36% of the company’s stock.
Several hedge funds have recently modified their holdings of AKAO. State Street Corp lifted its position in shares of Achaogen by 302.6% during the second quarter. State Street Corp now owns 1,677,097 shares of the biopharmaceutical company’s stock worth $36,444,000 after purchasing an additional 1,260,509 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in Achaogen by 106.7% in the second quarter. TimesSquare Capital Management LLC now owns 1,088,300 shares of the biopharmaceutical company’s stock worth $23,649,000 after acquiring an additional 561,700 shares during the last quarter. Franklin Resources Inc. bought a new position in Achaogen in the second quarter worth about $8,692,000. Vanguard Group Inc. lifted its holdings in Achaogen by 32.2% in the second quarter. Vanguard Group Inc. now owns 1,410,129 shares of the biopharmaceutical company’s stock worth $30,641,000 after acquiring an additional 343,428 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Achaogen by 619.5% in the second quarter. Northern Trust Corp now owns 341,367 shares of the biopharmaceutical company’s stock worth $7,418,000 after acquiring an additional 293,920 shares during the last quarter. 83.81% of the stock is currently owned by institutional investors and hedge funds.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.